Literature DB >> 11508324

Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life.

T Ushiroyama1, A Ikeda, M Ueki.   

Abstract

The present study evaluated the effects of clenbuterol and propiverine therapy on postmenopausal urinary incontinence. The patients consisted of 89 postmeopausal women with stress or urge incontinence who had consulted our out-patient clinic between March 1994 and February 1999. Patients were treated with either clenbuterol for stress incontinence or propiverine for urge incontinence. The administration period for both drugs was eight weeks. The cure rates for clenbuterol and propiverine were 41.2% and 52.6%, respectively. Both treatments significantly decreased the frequencies of incontinence, 24-h. voiding and nocturnal voiding, and both resulted in an overall clinical improvement. Furthermore, the two treatments resulted in significant subjective improvements in quality of life. We conclude that both medical treatments resulted in an improvement in urinary incontinence and contributed to overall quality of life. The present study demonstrated the necessity of contributed urinary incontinence with improvement in quality of life of postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11508324

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  2 in total

Review 1.  Incontinence-specific quality of life measures used in trials of treatments for female urinary incontinence: a systematic review.

Authors:  Sue Ross; Dana Soroka; Amalia Karahalios; Cathryn M A Glazener; E Jean C Hay-Smith; Harold P Drutz
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-07-16

2.  β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder.

Authors:  Brian J Limberg; Karl-Erik Andersson; F Aura Kullmann; Glenna Burmer; William C de Groat; Jan S Rosenbaum
Journal:  Cell Tissue Res       Date:  2010-10-16       Impact factor: 5.249

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.